Blepharospasm Clinical Trial
Official title:
Role of the Cortical Medial Frontal Areas in Blepharospasm
This study will examine the role of certain areas of the brain in blepharospasm, a type of
dystonia (abnormality of movement and muscle tone) that causes unwanted or uncontrollable
blinking or closing of the eyelids. The study will compare brain activity in healthy
volunteers and in people with blepharospasm to find differences in the brain that may lead to
better treatments for dystonia.
Healthy volunteers and people with blepharospasm who are 18 years of age and older may be
eligible for this study. All candidates are screened with a medical history. People with
blepharospasm also have a physical examination and blepharospasm rating.
Participants undergo transcranial magnetic stimulation (TMS) and electromyography (EMG) in
two 4-hour sessions, separated by 1 to 7 days.
TMS
A wire coil is held on the subject's scalp. A brief electrical current is passed through the
coil, creating a magnetic pulse that stimulates the brain. The subject hears a click and may
feel a pulling sensation on the skin under the coil. There may be a twitch in muscles of the
face, arm or leg. During the stimulation, subjects may be asked to tense certain muscles
slightly or perform other simple actions. Repetitive TMS involves repeated magnetic pulses
delivered in short bursts of impulses. Subjects receive 60 pulses per minute over 15 minutes.
EMG
Surface EMG is done during TMS to measure the electrical activity of muscles. For this test,
electrodes (small metal disks) are filled with a conductive gel and taped to the skin of the
face....
Objectives
This proposal will evaluate the role of an increase in excitability of the orbicularis oculi
(OO) muscle representation in the medial frontal areas (supplementary motor areas, SMA) and
anterior rostral cingulate: M3) in excessive blinking in patients with benign essential
blepharospasm (BEB). We hypothesize that:
1. at rest, the decrease of the MEP after 15 minutes of 1Hz rTMS, targeting the SMA-M3, is
more prominent in patients with BEP than in healthy control subjects,
2. at rest, the decrease of the MEP after 15 minutes of 1Hz rTMS targeting M1, is almost
the same in patients with BEP and in healthy control subjects,
3. at rest, sICI of OO muscle will be decreased and ICF increased after stimulation of the
SMA-M3 facial cortical area, in patients with BEP compared to healthy control subjects,
4. at rest sICI and ICF of the OO muscle will be the same after stimulation of the M1
facial area in patients with BEP and healthy control subjects,
5. in healthy control subjects facilitation of the MEPs evoked from M1 is more prominent
during voluntary blinking,
6. in healthy control subjects facilitation of the MEP evoked from SMA-M3 is more prominent
during involuntary blinking,
7. in patients with BEB there is facilitation of MEPs evoked from M1 and SMA-M3 during
voluntary and involuntary blinking.
8. it is possible to evoke consistent and reproducible motor evoked responses (MEP) in the
orbicularis oculi (OO) muscles by stimulating the two main cortical representations of
upper facial region: in the medial frontal wall (SMA and cingulate cortex - its rostral
part, M3) and in the primary motor cortex (M1) with transcranial magnetic stimulation
(TMS).
Study population
36 patients with BEB but without severe forceful closure of eyelids, 36 normal volunteers.
Study design
Subjects will have 3 visits:
Visit 1: screening and blepharospasm score
Visit 2: stimulation of the OO muscle representation in SMA-M3 using low frequency rTMS (1Hz)
with the Hesed coil (designed to stimulate deep brain).
Visit 3: stimulation of the OO muscle representation in M1 using low frequency rTMS (1Hz)
using a standard eight-shaped coil.
Visits 2 and 3: single pulse TMS will be used to evoke MEPs from OO muscles. Paired pulse TMS
will be used to assess sICI from OO muscles. The order of visits 2 and 3 will be randomly
assigned.
Outcome measures
The main outcome measures will be the sizes of OO muscle MEPs and the amount of sICI assessed
before and after 15 minutes of low frequency rTMS. The secondary outcome measures will be the
sizes of OO muscle MEPs assessed before and during voluntary and involuntary blinks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01686061 -
Blepharospasm Patient Survey for Patients With Blepharospasm
|
||
Completed |
NCT00535938 -
MDs on Botox Utility (MOBILITY)
|
N/A | |
Recruiting |
NCT05027997 -
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
|
Phase 2 | |
Terminated |
NCT03263000 -
Photic Blink Reflex in People With Blepharospasm and Increased Blinking
|
||
Completed |
NCT03938363 -
Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia
|
N/A | |
Completed |
NCT02947815 -
Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
|
Phase 2/Phase 3 | |
Completed |
NCT00406367 -
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
|
Phase 3 | |
Completed |
NCT00682760 -
Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm
|
Phase 3 | |
Completed |
NCT00210431 -
Post Marketing Surveillance Study of Dysport
|
||
Completed |
NCT05103202 -
Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
|
||
Completed |
NCT04423341 -
Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm
|
Phase 2/Phase 3 | |
Completed |
NCT03269123 -
A Mechanical Device for Blepharospasm
|
N/A | |
Completed |
NCT00411255 -
Brain Stimulation to Treat Blepharospasm or Meige Syndrome
|
Phase 2 | |
Completed |
NCT00761592 -
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
|
Phase 4 | |
Completed |
NCT00001784 -
Mexiletine for the Treatment of Focal Dystonia
|
Phase 2 | |
Recruiting |
NCT04939909 -
Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm
|
Early Phase 1 | |
Completed |
NCT03508882 -
Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm
|
Phase 4 | |
Completed |
NCT01814774 -
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
|
N/A | |
Completed |
NCT00234507 -
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
|
Phase 2 | |
Recruiting |
NCT05618470 -
Wumeiwan Jiawei Fang Use in Patients With Blepharospasm
|
Phase 2/Phase 3 |